%D8%B3%D9%88%D8%B1%D8%A7%D9%86%D9%8A%D8%A8Category:SorafenibSorafenibSorafenibSorafenibSorafeniib%D8%B3%D9%88%D8%B1%D8%A7%D9%81%D9%86%DB%8C%D8%A8SorafenibiSoraf%C3%A9nib%D7%A1%D7%95%D7%A8%D7%90%D7%A4%D7%A0%D7%99%D7%91Sorafenib%E3%82%BD%E3%83%A9%E3%83%95%E3%82%A7%E3%83%8B%E3%83%96Sorafenib%D0%A1%D0%BE%D1%80%D0%B0%D1%84%D0%B5%D0%BD%D0%B8%D0%B1SorafenibSorafenibSorafenib%D0%A1%D0%BE%D1%80%D0%B0%D1%84%D0%B5%D0%BD%D1%96%D0%B1Q421136%E7%B4%A2%E6%8B%89%E9%9D%9E%E5%B0%BC
about
B-Raf proto-oncogene, serine/threonine kinaseCyclin dependent kinase 19Kinase insert domain receptorPlatelet derived growth factor receptor, beta polypeptideFMS-like tyrosine kinase 4Discoidin domain receptor tyrosine kinase 2Raf-1 proto-oncogene, serine/threonine kinaseRet proto-oncogeneFms related receptor tyrosine kinase 3Cyclin dependent kinase 8Fibroblast growth factor receptor 1KIT proto-oncogene, receptor tyrosine kinase
P129
P3781
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With SorafenibSorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid LeukemiaSorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform NeurofibromasBAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's SarcomaEffect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3 Internal Tandem Duplication (ITD)A Study to Evaluate SHR-1210 in Combination With FOLFOX4 Regimen as First-Line Therapy in Subjects With Advanced HCCHepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular CarcinomaCombination of Sorafenib and Radiation for Brain Metastases and Primary Brain TumorsPhase I Study of Vorinostat and Sorafenib in Advanced CancerCO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary CarcinomaPhase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast CancerClinical Trial on the Mixture of G, C and S in Treatment of Patients With RCCValproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid TumorPhase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) TherapyAn Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell CarcinomaA Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaSorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III MelanomaA Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic MelanomaSorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney CancerDose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)Sorafenib in BAC or Never-Smokers With Lung AdenocarcinomaPemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerMitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic MelanomaCisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung CancerDrug Interaction Study of Sorafenib and Rapamycin in Advanced MalignanciesPhase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney CancerErlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeSafety and Toxicity Study of Sorafenib in Patients With Kidney CancerPhase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic CancerEfficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AMLVelcade and Sorafenib in Unresected or Metastatic Renal Cell CarcinomaHepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese PatientsSorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or CholangiocarcinomaSorafenib for Imatinib/Sunitinib-failed GIST
P4844
Sorafenib / Sirolimus combination therapySorafenib / Panitumumab combination therapycarboplatin / paclitaxel / sorafenib combination therapydocetaxel trihydrate / sorafenib / carboplatin combination therapysorafenib / temsirolimus / Bevacizumab combination therapyFerroptosisrefametinib / sorafenib combination therapySorafenib / Azacytidine combination therapySorafenib / MEK inhibitor combination therapyMelanoma
P527
Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study.Locoregional and systemic therapy for hepatocellular carcinoma.Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer.[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysisImproved drug targeting to liver tumor by sorafenib-loaded folate-decorated bovine serum albumin nanoparticlesImplementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in TaiwanA real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular CarcinomaDesmoid tumor: A focus set on a challenging but understudied rare diseasePKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinomaThe Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma ProgressionMetastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapyMetabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysisTumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinomaA rare case of sorafenib-induced severe hyponatremiaMiR-374b re-sensitizes hepatocellular carcinoma cells to sorafenib therapy by antagonizing PKM2-mediated glycolysis pathwayGenome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with SorafenibHexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular CarcinomaProfile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trialsSorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular CarcinomaUBE2C functions as a potential oncogene by enhancing cell proliferation, migration, invasion, and drug resistance in hepatocellular carcinoma cellsFOXM1-Mediated LINC-ROR Regulates the Proliferation and Sensitivity to Sorafenib in Hepatocellular CarcinomaEfficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studiesPhase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancerPreclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imagingTargeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenibEfficacy of on-demand intrahepatic arterial therapy in combination with sorafenib for advanced hepatocellular carcinomaTargeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyondImpact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristicImproved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGDTreatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysisComparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacyβ-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular CarcinomaNovel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma CellsTransarterial Chemoembolization (TACE) Combined with Sorafenib TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching StudyRole of local treatment including radiotherapy in Barcelona Clinic of Liver Cancer stage C patients: a nationwide cohort analysis in South KoreaEGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYCEmerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemiaADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma
P921
Q21109218-B654DE24-BED4-4197-94C2-5E8FCB4F4533Q21156191-27944585-820C-40A1-A9E0-5BDE1EDF3354Q21172390-97C9D69A-B0B4-438D-9BEC-D8EDC8F74363Q21983261-0A42A69F-64C3-41B6-AF86-C6573175B8ECQ21992684-D7578BCB-D7EB-47C9-AD96-8F6C1B120C61Q4036865-59772CBC-4D35-4DAB-A690-F80988D6A5DAQ410434-E2A4A295-40F7-4657-9AD3-96810727C675Q415976-777EBB59-B9C7-47AC-A97C-D4B560F912F6Q5009781-0965F1FE-12CC-4462-87CE-B925703861C3Q5198254-67845282-84EA-4841-9215-AD420CC90B0CQ5446453-7AF586B4-CD59-412B-A655-AD5E15982734Q909409-4A303C95-3206-423D-AFED-3DE4C03A949D
P129
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Sorafenib
@de
Sorafenib
@es
Sorafenib
@nl
Sorafenib
@pl
Sorafenib
@sh
Sorafenib
@sl
Sorafenib
@sr
Sorafenib
@vi
Sorafenibi
@fi
Sorafeniib
@et
type
label
Sorafenib
@de
Sorafenib
@es
Sorafenib
@nl
Sorafenib
@pl
Sorafenib
@sh
Sorafenib
@sl
Sorafenib
@sr
Sorafenib
@vi
Sorafenibi
@fi
Sorafeniib
@et
altLabel
4-(4-((((4-Chloro-3-(trifluoro ...... N-methyl-2-pyridinecarboxamide
@en
BAY 43-9006
@en
C21H16ClF3N4O3
@fr
N-(4-Chloro-3-(trifluoromethyl ...... moyl)-4-pyridyloxy)phenyl)urea
@en
N-(4-Chloro-3-(trifluoromethyl ...... moyl)-4-pyridyloxy)phenyl)urea
@en
Nexavar
@de
Nexavar
@fi
Nexavar
@pl
Nexavar
@zh
Nexavar®
@en
prefLabel
Sorafenib
@de
Sorafenib
@es
Sorafenib
@nl
Sorafenib
@pl
Sorafenib
@sh
Sorafenib
@sl
Sorafenib
@sr
Sorafenib
@vi
Sorafenibi
@fi
Sorafeniib
@et